文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machine
侵权投诉

Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machine

VirtualScreeningofMultitargetKinaseInhibitors

articles

Table3.DistributionofTop6ScaffoldsinDual-Inhibitorsof7Intra-PTKGroupKinaseCombinationsofEGFR,VEGFR,PDGFR,FGFR,SrcandLck,andNon-Dual-InhibitorsoftheConstituentKinases

percentageofinhibitorscontainingscaffold

kinasepair

datasets

A63.8(37/58)0.2(3/1316)20.3(126/622)54.9(39/71)0.1(1/1303)25.5(100/392)33.9(38/112)0.2(2/1262)18.2(136/748)27.9(17/61)0.7(8/1232)5.6(25/445)67.4(155/230)1.8(8/450)11.2(26/233)76.1(143/188)2.9(14/492)3.7(25/672)0(0/56)21.6(174/804)5.9(26/450)

B

C

D

E

F

EGFR-PDGFRdual-inhibitors

EGFRnon-dual-inhibitorsPDGFRnon-dual-inhibitors

EGFR-FGFRdual-inhibitors

EGFRnon-dual-inhibitorsFGFRnon-dual-inhibitors

EGFR-Srcdual-inhibitors

EGFRnon-dual-inhibitorsSrcnon-dual-inhibitors

VEGFR-Lckdual-inhibitors

VEGFRnon-dual-inhibitorsLcknon-dual-inhibitors

PDGFR-FGFRdual-inhibitors

PDGFRnon-dual-inhibitorsFGFRnon-dual-inhibitors

PDGFR-Srcdual-inhibitors

PDGFRnon-dual-inhibitorsSrcnon-dual-inhibitors

Src-Lckdual-inhibitors

Srcnon-dual-inhibitorsLcknon-dual-inhibitors0(0/58)0(0/58)1.7(1/58)8.6(5/58)0(0/58)6.3(83/1316)1.2(16/1316)7.7(101/1316)0(0/1316)0(0/1316)0(0/622)0(0/622)0(0/622)7.1(44/622)0(0/622)0(0/71)0(0/71)32.4(23/71)7.0(5/71)0(0/71)6.4(83/1303)1.2(16/1303)6.1(79/1303)0(0/1303)0(0/1303)0(0/392)0(0/392)2.3(9/392)10.0(39/392)0.3(1/392)25.9(29/112)19.6(22/112)4.5(5/112)2.7(3/112)0(0/112)4.3(54/1262)1.6(20/1262)7.7(97/1262)0.2(2/1262)0(0/1262)10.4(78/748)0.8(6/748)5.0(37/748)1.60(12/748)2.8(21/748)29.5(18/61)0(0/61)0(0/61)0(0/61)34.4(21/61)0.8(10/1232)0(0/1232)5.4(66/1232)4.7(58/1232)0(0/1232)10.3(46/445)0(0/445)1.6(7/445)0(0/445)1.6(7/445)0(0/230)0(0/230)0(0/230)17.8(41/230)0(0/230)0(0/450)0(0/450)0.2(1/450)1.8(8/450)0(0/450)0(0/233)0(0/233)13.7(32/233)1.3(3/233)0.4(1/233)0(0/188)0(0/188)0(0/188)6.9(13/188)0(0/188)0(0/492)0(0/492)0.2(1/492)7.3(36/492)0(0/492)15.9(107/672)1.9(13/672)6.3(42/672)0.3(2/672)3.1(21/672)57.1(32/56)0(0/56)1.8(1/56)1.8(1/56)37.5(21/56)9.3(75/804)1.6(13/804)5.1(41/804)1.9(15/804)0(0/804)7.8(35/450)0(0/450)1.3(6/450)0(0/450)2(9/450)

VirtualScreeningPerformanceofCombinatorial

SVMinSearchingKinaseDual-InhibitorsfromLargeLibraries.TheVSperformanceofC-SVMinidentifyingdual-inhibitorsofthe11kinasepairsissummarizedinTable4andfurthershowninFigure4.TheparametersofthedevelopedSVMclassi cationmodelsfortheevaluatedkinasesareintherangeofσ)0.5-0.8.Thedual-inhibitoryieldsare27.6%forEGFR-PDGFR,40.9%forEGFR-FGFR,26.8%forEGFR-Src,52.6%forVEGFR-Lck,33.9%forPDGFR-FGFR,38.3%forPDGFR-Src,48.2%forSrc-Lck,52.3%forCDK1-CDK2,49.0%forCDK1-GSK3,57.3%forCDK2-GSK3,and12.2%forCDK1-VEGFRrespectively.Theyieldsfortheintra-PTKgroupandintra-CMGCgroupkinasepairsarecomparabletotheexpected25%-49%yieldsofcombinationsofgoodVStoolswithindividualyieldsof50%-70%.Therefore,C-SVMshowreasonablygoodcapabilityinidentifyingmultitargetagentsforkinasepairswithinaproteinkinasegroupwithoutrequiringexplicitknowledgeofmultitargetagents.However,theyieldfortheinter-PTK-CMGCkinasegroupCDK1-VEGFRkinasepairisonly12.2%,whichissigni cantlylowerthanthosefortheintra-PTKgroupandintra-CMGCgroupkinasepairs.StructuralanalysisoftheinhibitorsofCDK1andVEGFRbindingsiteshasrevealedthatinhibitorsgenerallymakeextensivefavorablevanderWaalscontactsandseveralhydrogenbondswithLys33,Leu83andAsp86atthehingeregionofCDK1,andwithCys919,Asn923,Cys1045andAsp1046atthehingeregionofVEGFRrespectively,relativelysmallstructuralchangesmayeasilyreducetheoptimal ttothebindingsite,andsomedual-inhibitorsareabletobindtobothkinasesbecauseoftheir

structural exibilitytotoleratethedifferentbindingsitegeometryandtoformalternativehydrogenbonds.60Insomecases,dualselectivityofinhibitorsofinter-kinase-groupkinasepairsmayrequirestructural exibilityto tinahydrophobicpocketconservedinbothkinaseclasses.61Suchspecialstructuralfeaturesindual-inhibitorsofinterkinase-groupkinasepairsarenotnecessarilyneededandthusmaynotbefoundinnon-dual-inhibitorsofindividualkinasesusedinourtrainingdatasets,whichcouldlikelybeanimportantreasonforthereducedyieldofC-SVMinidentifyingCDK1-VEGFRdual-inhibitors.ThesmallernumberofknownCDK1-VEGFRdual-inhibitorsmayalsoaffecttheaccurateassessmentofVSoutcome.

TargetselectivitywastestedbyusingC-SVMtoscreenthe233-1,316non-dual-inhibitorsofthe11kinasepairs,whichmisidenti ed9.2%and14.3%ofthenon-dual-inhibitorsofthekinasepairasdual-inhibitorsforEGFR-PDGFR,10.1%and8.7%forEGFR-FGFR,12.9%and11.1%forEGFR-Src,6.6%and29.2%forVEGFR-Lck,15.6%and22.3%forPDGFR-FGFR,25.8%and11.6%for

(60)Kuo,G.H.;Wang,A.;Emanuel,S.;Deangelis,A.;Zhang,R.;

Connolly,P.J.;Murray,W.V.;Gruninger,R.H.;Sechler,J.;Fuentes-Pesquera,A.;Johnson,D.;Middleton,S.A.;Jolliffe,L.;Chen,X.Synthesisanddiscoveryofpyrazine-pyridinebiheteroarylasanovelseriesofpotentvascularendothelialgrowthfactorreceptor-2inhibitors.J.Med.Chem.2005,48(6),1886–900.(61)Apsel,B.;Blair,J.A.;Gonzalez,B.;Nazif,T.M.;Feldman,M.E.;

Aizenstein,B.;Hoffman,R.;Williams,R.L.;Shokat,K.M.;Knight,Z.A.Targetedpolypharmacology:discoveryofdualinhibitorsoftyrosineandphosphoinositidekinases.Nat.Chem.Biol.2008,4(11),691–9.

VOL.7,NO.5MOLECULARPHARMACEUTICS1553

上一页第9页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email